Search

Your search keyword '"Manuel Criollo-Orozco"' showing total 2 results
Start Over Author "Manuel Criollo-Orozco" Topic newcastle disease virus
2 results on '"Manuel Criollo-Orozco"'

1. A Recombinant Turkey Herpesvirus Expressing the F Protein of Newcastle Disease Virus Genotype XII Generated by NHEJ-CRISPR/Cas9 and Cre-LoxP Systems Confers Protection against Genotype XII Challenge in Chickens

Author

Katherine Calderón, Aldo Rojas-Neyra, Brigith Carbajal-Lévano, Luis Luján-Valenzuela, Julio Ticona, Gisela Isasi-Rivas, Angela Montalvan, Manuel Criollo-Orozco, Edison Huaccachi-Gonzáles, Luis Tataje-Lavanda, Karla Lucia F. Alvarez, Manolo Fernández-Sánchez, Manolo Fernández-Díaz, Na Tang, Yongxiu Yao, and Venugopal Nair

Subjects
Newcastle disease virus, fusion gene, genotype XII, Turkey herpesvirus, CRISPR/Cas9, NHEJ, Microbiology, QR1-502
Abstract

In this study, we developed a new recombinant virus rHVT-F using a Turkey herpesvirus (HVT) vector, expressing the fusion (F) protein of the genotype XII Newcastle disease virus (NDV) circulating in Peru. We evaluated the viral shedding and efficacy against the NDV genotype XII challenge in specific pathogen-free (SPF) chickens. The F protein expression cassette was inserted in the unique long (UL) UL45–UL46 intergenic locus of the HVT genome by utilizing a clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 gene-editing technology via a non-homologous end joining (NHEJ) repair pathway. The rHVT-F virus, which expressed the F protein stably in vitro and in vivo, showed similar growth kinetics to the wild-type HVT (wtHVT) virus. The F protein expression of the rHVT-F virus was detected by an indirect immunofluorescence assay (IFA), Western blotting, and a flow cytometry assay. The presence of an NDV-specific IgY antibody was detected in serum samples by an enzyme-linked immunosorbent assay (ELISA) in SPF chickens vaccinated with the rHVT-F virus. In the challenge experiment, the rHVT-F vaccine fully protects a high, and significantly reduced, virus shedding in oral at 5 days post-challenge (dpc). In conclusion, this new rHVT-F vaccine candidate is capable of fully protecting SPF chickens against the genotype XII challenge.

Published
2022
Full Text
View/download PDF

2. Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease

Author

Manolo Fernández, Díaz, Katherine, Calderón, Aldo, Rojas-Neyra, Vikram N, Vakharia, Ricardo, Choque-Guevara, Angela, Montalvan-Avalos, Astrid, Poma-Acevedo, Dora, Rios-Matos, Andres, Agurto-Arteaga, Maria de Grecia, Cauti-Mendoza, Norma, Perez-Martinez, Gisela, Isasi-Rivas, Luis, Tataje-Lavanda, Yacory, Sernaque-Aguilar, Freddy, Ygnacio, Manuel, Criollo-Orozco, Edison, Huaccachi-Gonzalez, Elmer, Delgado-Ccancce, Doris, Villanueva-Pérez, Ricardo, Montesinos-Millán, Kristel, Gutiérrez-Manchay, Katherinne, Pauyac-Antezana, Ingrid, Ramirez-Ortiz, Stefany, Quiñones-Garcia, Yudith, Cauna-Orocollo, Katherine, Vallejos-Sánchez, Angela, Rios-Angulo, Dennis, Núñez-Fernández, Mario I, Salguedo-Bohorquez, Julio, Ticona, Manolo, Fernández-Sánchez, Eliana, Icochea, Luis A, Guevara-Sarmiento, and Mirko, Zimic

Subjects
Mice, Vaccines, Synthetic, SARS-CoV-2, Cricetinae, Vaccination, Newcastle disease virus, Animals, COVID-19, Viral Vaccines, Antibodies, Viral, Antibodies, Neutralizing, Administration, Intranasal
Abstract

The coronavirus disease-19 (COVID-19) pandemic has already claimed millions of lives and remains one of the major catastrophes in the recorded history. While mitigation and control strategies provide short term solutions, vaccines play critical roles in long term control of the disease. Recent emergence of potentially vaccine-resistant and novel variants necessitated testing and deployment of novel technologies that are safe, effective, stable, easy to administer, and inexpensive to produce. Here we developed three recombinant Newcastle disease virus (rNDV) vectored vaccines and assessed their immunogenicity, safety, and protective efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters. Intranasal administration of rNDV-based vaccine candidates elicited high levels of neutralizing antibodies. Importantly, the nasally administrated vaccine prevented lung damage, and significantly reduced viral load in the respiratory tract of vaccinated animal which was compounded by profound humoral immune responses. Taken together, the presented NDV-based vaccine candidates fully protected animals against SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial as a promising tool in the fight against COVID-19.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results